Melanoma at a glance
- Melanoma is a cancer of melanocytes, the cells that produce pigment. It can start in skin and, less commonly, in the eye, mucosal tissue, or another site.
- A new or changing spot, an unusual lesion, or a sore that does not heal deserves examination, but appearance alone cannot confirm or exclude melanoma.
- Diagnosis requires a biopsy reviewed by pathology. Tumor thickness, ulceration, lymph nodes, spread, and selected gene changes help guide staging and treatment.
- Localized melanoma is generally treated surgically. Higher-risk or advanced disease may involve immunotherapy, targeted therapy, radiation, additional surgery, or clinical trials.
- Prompt assessment is important, while emergency care is needed for severe breathing difficulty, new neurologic symptoms, uncontrolled bleeding, or serious treatment reactions.

What melanoma is
Melanoma begins when melanocytes develop cancerous changes. Most melanomas discussed in general health information arise in the skin, but melanoma can also occur in the eye or mucosal surfaces. These forms differ in biology, staging, and treatment. This page gives a broad patient-level overview with emphasis on cutaneous melanoma and does not replace specialist information for ocular or mucosal disease.
Melanoma is not the same as basal cell or squamous cell skin cancer. All can be serious, but their usual behavior, staging, and treatment differ. Melanoma can spread to lymph nodes or distant organs, which is why accurate biopsy and stage matter. Early melanoma confined to its original site is often highly treatable.
A photograph, phone application, mole chart, or ABCDE checklist cannot make a diagnosis. Some harmless moles look unusual, and some melanomas do not fit a classic picture. Amelanotic melanoma may have little pigment. Lesions can also develop under nails, on palms or soles, on the scalp, or in areas not regularly exposed to sun.
Changes that should be examined
Common warning patterns include asymmetry, an irregular border, varied color, a changing diameter, or evolution over time. Evolution is particularly important: a spot that changes in size, shape, color, texture, sensation, or bleeding pattern deserves attention. An “ugly duckling” that looks different from a person’s other moles can also be concerning.
Other reasons for assessment include a new persistent pigmented or nonpigmented lesion, a sore that does not heal, repeated bleeding without clear injury, itching or tenderness in a changing spot, pigment spreading beyond a border, or a dark line under a nail that is new or changing. These signs have many possible causes and are not proof of cancer.
People with darker skin can develop melanoma. Lesions may occur on less sun-exposed sites, including palms, soles, and nails. Delayed recognition can worsen outcomes, so concern should not be dismissed because a person does not fit a stereotyped risk profile.
When to seek prompt or emergency care
A suspicious lesion usually needs a timely clinical appointment rather than an emergency department visit. Seek prompt assessment for a rapidly changing spot, recurrent unexplained bleeding, a new firm lump near a prior melanoma site, an enlarging lymph node, or a persistent lesion under a nail, on a palm or sole, or on a mucosal surface.
Call emergency services for a new seizure, sudden one-sided weakness, trouble speaking, severe breathing difficulty, coughing up significant blood, uncontrolled bleeding, fainting, or another rapidly dangerous symptom in a person with known cancer. These signs have multiple possible causes but require immediate evaluation.
People receiving immunotherapy or other systemic treatment should follow the oncology team’s urgent instructions. New severe diarrhea, chest pain, breathing difficulty, jaundice, profound weakness, confusion, severe rash with blistering, or high fever can reflect a serious treatment effect or infection. Do not wait for the next routine visit.
Risk factors and prevention
Ultraviolet radiation from sunlight and indoor tanning damages skin cells and contributes to melanoma risk. Risk is also associated with skin that burns easily, severe blistering sunburns, many moles, atypical moles, a personal or family history of melanoma, certain inherited syndromes, and weakened immunity. No risk factor guarantees that melanoma will occur, and absence of a known factor does not rule it out.
Reduce avoidable UV exposure by seeking shade, wearing protective clothing, a broad-brimmed hat and sunglasses, and using broad-spectrum sunscreen according to the label. Reapply when directed and after swimming or heavy sweating. Sunscreen is one part of protection, not permission to extend time in intense sun. Avoid indoor tanning devices.
People at higher risk may be advised to have professional skin examinations and to monitor their skin between visits. The interval should reflect personal history, number and type of moles, family history, immune status, and clinician guidance. Taking consistent photographs can help document change, but an image comparison cannot replace examination and biopsy.
How melanoma is diagnosed
The clinician reviews the lesion’s history, examines the skin and nearby lymph nodes, and considers personal and family risk. Dermoscopy can magnify structures not visible to the naked eye and help decide which lesion needs biopsy. It still does not provide a final tissue diagnosis.
Biopsy removes all or part of a suspicious lesion for microscopic examination. The technique should preserve information needed to measure depth and other features. A pathology report may describe melanoma type, thickness, ulceration, mitotic activity, margins, and other findings. Because difficult lesions can be interpreted differently, expert pathology review or a second opinion may be appropriate.
After diagnosis, staging determines how far cancer has spread. Tumor thickness and ulceration are important. Depending on risk, evaluation may include lymph-node mapping and sentinel lymph-node biopsy, imaging, and testing the tumor for gene changes such as BRAF. Not everyone needs every scan or node procedure. Testing should answer a question that can change management.
Understanding stage without predicting one person
Stage 0 melanoma is limited to the epidermis and is also called melanoma in situ. Invasive melanoma extends deeper. Stages I and II are generally localized, with risk shaped by thickness, ulceration, and other features. Stage III involves regional nodes or nearby skin or lymphatic spread. Stage IV means distant spread.
Stage provides a framework for treatment and prognosis, but it does not give an exact personal timeline. Age, general health, tumor biology, treatment response, and access to care also matter. Online survival figures describe groups diagnosed and treated in earlier periods and cannot predict what will happen to one individual today.
Treatment principles
Surgery is the main treatment for localized cutaneous melanoma. The surgeon removes the melanoma with a margin of normal-appearing tissue based on pathology and clinical guidance. Sentinel-node evaluation may be discussed for selected invasive melanomas. More extensive lymph-node surgery is not automatic and depends on findings and current practice.
People with higher-risk disease may be offered treatment before or after surgery. Immunotherapy helps the immune system recognize or attack cancer but can also inflame healthy organs. Targeted therapy may be an option when the tumor has a specific molecular change. Radiation can treat selected sites or symptoms. Advanced disease may involve combinations and clinical trials.
Treatment choices change as evidence and approvals evolve. Benefits must be weighed against immune, cardiac, skin, liver, bowel, endocrine, neurologic, fertility, and other risks. Do not choose a product from a mutation result or stop therapy because of an online side-effect list. Contact the oncology team for new symptoms because early management can matter.
Follow-up and recurrence surveillance
Follow-up may include skin and lymph-node examinations, review of symptoms, and imaging for selected stages. The schedule depends on original stage, treatment, recurrence risk, immune status, and local practice. People with one melanoma have a greater risk of another melanoma, so ongoing skin awareness remains important.
Report a new changing lesion, lump, persistent unexplained pain, ongoing cough, neurologic change, severe headache, or unintended weight loss. Most such symptoms are not necessarily recurrence, but the oncology team can decide what needs investigation. Keep pathology, stage, molecular test, surgery, and treatment records for future care.
Fear of recurrence, body-image changes, scarring, lymphedema, fatigue, and treatment effects deserve support. Rehabilitation, mental-health care, social work, financial counseling, and palliative care can be used alongside cancer treatment. Palliative care focuses on symptoms and goals and is not limited to the end of life.
Preparing for dermatology or oncology care
Bring the date a lesion first appeared, photographs showing change, previous skin-biopsy reports, family cancer history, tanning and sunburn history, immune-suppressing medicines, and a complete medicine list. Do not cut, burn, or repeatedly traumatize the lesion before examination.
After diagnosis, ask for a copy of the pathology report and the exact stage. Clarify tumor thickness, ulceration, margins, whether expert pathology review is useful, whether node or imaging tests could change care, and whether molecular testing is needed. Ask about treatment goals, important risks, fertility, trials, follow-up, skin examinations, and urgent treatment symptoms.